WO2021263030A1 - Interventional device dressing system - Google Patents
Interventional device dressing system Download PDFInfo
- Publication number
- WO2021263030A1 WO2021263030A1 PCT/US2021/038963 US2021038963W WO2021263030A1 WO 2021263030 A1 WO2021263030 A1 WO 2021263030A1 US 2021038963 W US2021038963 W US 2021038963W WO 2021263030 A1 WO2021263030 A1 WO 2021263030A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dressing
- dressing system
- matrix
- interventional device
- medical device
- Prior art date
Links
- 229940030225 antihemorrhagics Drugs 0.000 claims abstract description 9
- 239000004599 antimicrobial Substances 0.000 claims abstract description 9
- 239000011159 matrix material Substances 0.000 claims abstract description 9
- 239000004814 polyurethane Substances 0.000 claims abstract description 3
- 229920002635 polyurethane Polymers 0.000 claims abstract description 3
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 11
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 11
- 239000005995 Aluminium silicate Substances 0.000 claims description 8
- 235000012211 aluminium silicate Nutrition 0.000 claims description 8
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical group O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 5
- 229920005830 Polyurethane Foam Polymers 0.000 claims description 4
- 239000011496 polyurethane foam Substances 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 230000002439 hemostatic effect Effects 0.000 claims description 3
- 239000002874 hemostatic agent Substances 0.000 abstract description 7
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0269—Tapes for dressing attachment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00412—Plasters use for use with needles, tubes or catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00646—Medication patches, e.g. transcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- IV intravenous
- vascular and nonvascular percutaneous medical devices such as IV catheters and drainage tubes are widely used with patients.
- the catheters or other percutaneous devices are inserted into a patient via an access location through the skin. This can provide an entryway for disease and is also a location of possible hemorrhage and/or thrombosis.
- the disclosed system is a wound or access location dressing device for use with a transcutaneous medical device such as a cannula, a catheter, or other transcutaneous interventional device.
- the dressing device is formed at least partially of a flexible hydrophillic polyurethane matrix, an antimicrobial agent contained within or coupled to the matrix, and a hemostatic agent contained within or coupled to the matrix.
- the dressing advantageously prevents microbial colonization of the dressing and stops or inhibits bleeding from the access location site without adversely affecting wound healing.
- the antimicrobial agent can be, for example, chlorhexidine gluconate (CHG)(or a salt thereof) such as in an amount to achieve an antimicrobial effect without adversely affecting wound healing.
- CHG chlorhexidine gluconate
- the hemostatic agent may be, for example, kaolin, an inorganic mineral that accelerates the body's natural clotting ability and produces no exothermic reaction thereof in an amount to achieve a hemostatic effect.
- the wound dressing can contain a broad-spectrum antimicrobial agent and a hemostatic agent with a moisture vapour permeable backing.
- the dressing can include one or more holes, slits, or cut-outs to allow insertion of an IV catheter line or other percutaneous or interventional device therethrough.
- the dressing contains sufficient quantities of the antimicrobial agent to ensure that a clear antimicrobial zone of inhibition can be maintained around the insertion site and to prevent microbial contamination of the dressing.
- the device also contains sufficient quantities of hemostatic agent in order to successfully control minor bleeding at the insertion site.
- Figure 1 shows a schematic representation of a wound dressing device.
- Figure 1 shows a schematic representation of a wound dressing
- the dressing contains, is coated with, or is otherwise coupled to an antimicrobial agent to help resist microbial colonization of the dressing.
- the dressing also contains, is coated with, or is otherwise coupled to a hemostatic agent such that it is configured to reduce a time of bleeding at the access device.
- the dressing may also include a moisture vapour permeable backing to allow for moisture transmission.
- the backing may, for example, comprise a thin polyurethane film.
- the antimicrobial agent can be, for example, chlorhexidine gluconate (CHG), such as in an amount to achieve an antimicrobial effect without adversely affecting wound healing.
- CHG chlorhexidine gluconate
- the hemostatic agent may be, for example, kaolin, an inorganic mineral that accelerates the body's natural clotting ability and produces no exothermic reaction thereof in an amount to achieve a hemostatic effect.
- the dressing may be secured to the access site in any of a variety of manners.
- the dressing includes an adhesive component.
- the dressing may also include a component that renders the dressing generally sterile. Sterilization may be carried out, for example, using gamma irradiation but other sterilization methods such as ethylene oxide sterilization may also be used.
- the wound dressing 105 may be a planar or bulk body that is sized and shaped to be positioned at, near, or around an access site of a patient.
- the dressing 105 may have at least one skin contacting surface that at least partially contacts a patient’s skin at or near the location of the access site when in use.
- the dressing 105 may include one or more holes, openings, slits, or cutouts 110 through which at least a portion of the interventional device can be positioned when the dressing is in place at the access site.
- Such holes, openings, slits, or cutouts 110 may be contained entirely within an outer perimeter of the dressing 105 as shown or may intersect the outer perimeter.
- the dressing may have any of a variety of shapes.
- the holes, openings, slits, or cutout is sized and shaped to seal around an outer contour shape of the interventional device, such as a catheter, which is considered as part of this disclosure.
- the interventional device may have a circular, non-circular, or irregular cross-sectional shape.
- the holes, openings, slits, or cutouts can be shaped to conforms or correspond to the outer-cross-sectional shape of the interventional device.
- the correspondence can be exact in an embodiment to encourage a seal between the opening and the outer contour of the interventional device.
- a separate seal member is positioned entirely or partially on or around the contour holes, openings, slits, or cutouts such that the seal member establishes a seal with the outer contour of the interventional device.
- the seal member can be configured to expand and seal in response to the seal member coming into contact with fluid, such as blood and/or into contact with a microbe.
- the seal member can be made of an entirely different material than one or more materials of the remainder of the dressing.
- the dressing device has an adhesive on the skin contacting surface to aid in site securement and also for removal and re- securement.
- the dressing 105 can effectively maintain antimicrobial efficacy over a period of time.
- the dressing can effectively maintain antimicrobial efficacy up to 7 days.
- the dressing can be at least partially formed of a polymeric base material, such as polyurethane foam.
- the dressing can be formed in concentrations of, for example, 8% (w/w) Kaolin, 11% (w/w) CHG, and 81% hydrophillic flexible polyurethane foam.
- the dressing is formed in a concentration of 5% (w/w) to 15% (w/w) Kaolin, 3%(w/w) to 12% (w/w) Kaolin, or 5% (w/w) to 20% (w/w) Kaolin.
- the dressing is formed in a concentration of 15% (w/w) to 25% (w/w) CHG, 10% (w/w) to 25% (w/w) CHG, 13% (w/w) to 28% (w/w) CHG, or 12%(w/w) to 20% (w/w) CHG.
- a remainder of the concentration can be a foam such as hydrophillic flexible polyurethane foam.
- the wound dressing is circular with an outer diameter of 0.6 to 2 inches.
- an access site is formed through the skin of the patient.
- the access site may be a surgical cut-down through the skin, a percutaneous puncture, or any other opening through the skin.
- An interventional device such as a catheter formed of an elongated body with an internal lumen is then inserted through the access site and into the patient.
- the dressing is positioned at or near the access site such that the skin contacting surface contacts the skin and at least a portion of the dressing is in contact with the opening in the skin.
- the dressing maintains antimicrobial efficacy as well as hemostasis at the access location.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
A wound or access location dressing device can be used with a transcutaneous medical device such as a cannula, a catheter, or other transcutaneous interventional device. The dressing device is formed at least partially of a flexible hydrophillic polyurethane matrix, an antimicrobial agent contained within or coupled to the matrix, and a hemostatic agent contained within or coupled to the matrix.
Description
INTERVENTIONAL DEVICE DRESSING SYSTEM
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. Patent Application Serial No.
16/913,182, filed June 26, 2020 and is incorporated herein by reference in its entirety.
BACKGROUND
[0002] Disclosed is a wound dressing system that can be used with intravenous (IV) catheter systems and other percutaneous devices.
[0003] Vascular and nonvascular percutaneous medical devices such as IV catheters and drainage tubes are widely used with patients. The catheters or other percutaneous devices are inserted into a patient via an access location through the skin. This can provide an entryway for disease and is also a location of possible hemorrhage and/or thrombosis. As a result, there is typically a need to provide a dressing around the access location for antimicrobial purposes and to deal with bleeding.
[0004] There remains a need for an effective dressing for use with IV catheters that stops bleeding and is an effective antimicrobial solution.
SUMMARY
[0005] The disclosed system is a wound or access location dressing device for use with a transcutaneous medical device such as a cannula, a catheter, or other transcutaneous interventional device. In an example embodiment, the dressing device is formed at least partially of a flexible hydrophillic polyurethane matrix, an antimicrobial agent contained within or coupled to the matrix, and a hemostatic agent contained within or coupled to the matrix. The dressing
advantageously prevents microbial colonization of the dressing and stops or inhibits bleeding from the access location site without adversely affecting wound healing.
[0006] The antimicrobial agent can be, for example, chlorhexidine gluconate (CHG)(or a salt thereof) such as in an amount to achieve an antimicrobial effect without adversely affecting wound healing.
[0007] The hemostatic agent may be, for example, kaolin, an inorganic mineral that accelerates the body's natural clotting ability and produces no exothermic reaction thereof in an amount to achieve a hemostatic effect.
[0008] The wound dressing can contain a broad-spectrum antimicrobial agent and a hemostatic agent with a moisture vapour permeable backing. The dressing can include one or more holes, slits, or cut-outs to allow insertion of an IV catheter line or other percutaneous or interventional device therethrough. The dressing contains sufficient quantities of the antimicrobial agent to ensure that a clear antimicrobial zone of inhibition can be maintained around the insertion site and to prevent microbial contamination of the dressing. The device also contains sufficient quantities of hemostatic agent in order to successfully control minor bleeding at the insertion site.
[0009] Other features and advantages should be apparent from the following description of various embodiments, which illustrate, byway of example, the principles of the disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 shows a schematic representation of a wound dressing device.
DETAILED DESCRIPTION
[0011] Figure 1 shows a schematic representation of a wound dressing
105 that is configured to control or regulate bleeding at the access sites of an interventional device, such as an IV catheter, percutaneous device, or other interventional device that extends through skin of a patient at the access site. The access site may be formed by a cut-down, puncture, skin opening, etc. The dressing contains, is coated with, or is otherwise coupled to an antimicrobial agent to help resist microbial colonization of the dressing. The dressing also contains, is coated with, or is otherwise coupled to a hemostatic agent such that it is configured to reduce a time of bleeding at the access device. The dressing may also include a moisture vapour permeable backing to allow for moisture transmission. The backing may, for example, comprise a thin polyurethane film.
[0012] The antimicrobial agent can be, for example, chlorhexidine gluconate (CHG), such as in an amount to achieve an antimicrobial effect without adversely affecting wound healing. The hemostatic agent may be, for example, kaolin, an inorganic mineral that accelerates the body's natural clotting ability and produces no exothermic reaction thereof in an amount to achieve a hemostatic effect.
[0013] The dressing may be secured to the access site in any of a variety of manners. In an embodiment, the dressing includes an adhesive component. The dressing may also include a component that renders the dressing generally sterile. Sterilization may be carried out, for example, using gamma irradiation but other sterilization methods such as ethylene oxide sterilization may also be used.
[0014] With reference still to Figure 1 , the wound dressing 105 may be a planar or bulk body that is sized and shaped to be positioned at, near, or around an access site of a patient. The dressing 105 may have at least one skin contacting surface that at least partially contacts a patient’s skin at or near the location of the access site when in use.
[0015] The dressing 105 may include one or more holes, openings, slits, or cutouts 110 through which at least a portion of the interventional device can be positioned when the dressing is in place at the access site. Such holes, openings, slits, or cutouts 110 may be contained entirely within an outer perimeter of the dressing 105 as shown or may intersect the outer perimeter. The dressing may have any of a variety of shapes. In an embodiment, the holes, openings, slits, or cutout is sized and shaped to seal around an outer contour shape of the interventional device, such as a catheter, which is considered as part of this disclosure. The interventional device may have a circular, non-circular, or irregular cross-sectional shape. The holes, openings, slits, or cutouts can be shaped to conforms or correspond to the outer-cross-sectional shape of the interventional device. The correspondence can be exact in an embodiment to encourage a seal between the opening and the outer contour of the interventional device. In an example, a separate seal member is positioned entirely or partially on or around the contour holes, openings, slits, or cutouts such that the seal member establishes a seal with the outer contour of the interventional device. In another embodiment, there is a gap between an outer edge of the hole, opening, slit, or cutout and the seal member, with the seal member configured to expand and engage in a sealing manner with the interventional device. The seal member can be configured to expand and seal in response to the seal member coming into contact with fluid, such as blood and/or into contact with a
microbe. The seal member can be made of an entirely different material than one or more materials of the remainder of the dressing.
[0016] In one embodiment, the dressing device has an adhesive on the skin contacting surface to aid in site securement and also for removal and re- securement.
[0017] The dressing 105 can effectively maintain antimicrobial efficacy over a period of time. In an example, the dressing can effectively maintain antimicrobial efficacy up to 7 days.
[0018] The dressing can be at least partially formed of a polymeric base material, such as polyurethane foam. In a non-limiting example, the dressing can be formed in concentrations of, for example, 8% (w/w) Kaolin, 11% (w/w) CHG, and 81% hydrophillic flexible polyurethane foam. In another example embodiment, the dressing is formed in a concentration of 5% (w/w) to 15% (w/w) Kaolin, 3%(w/w) to 12% (w/w) Kaolin, or 5% (w/w) to 20% (w/w) Kaolin. In an embodiment, the dressing is formed in a concentration of 15% (w/w) to 25% (w/w) CHG, 10% (w/w) to 25% (w/w) CHG, 13% (w/w) to 28% (w/w) CHG, or 12%(w/w) to 20% (w/w) CHG. A remainder of the concentration can be a foam such as hydrophillic flexible polyurethane foam.
[0019] In an example embodiment the wound dressing is circular with an outer diameter of 0.6 to 2 inches.
[0020] In an example method of use, an access site is formed through the skin of the patient. As mentioned, the access site may be a surgical cut-down through the skin, a percutaneous puncture, or any other opening through the skin.
An interventional device, such as a catheter formed of an elongated body with an
internal lumen is then inserted through the access site and into the patient. The dressing is positioned at or near the access site such that the skin contacting surface contacts the skin and at least a portion of the dressing is in contact with the opening in the skin. As mentioned, the dressing maintains antimicrobial efficacy as well as hemostasis at the access location.
[0021] While this specification contains many specifics, these should not be construed as limitations on the scope of an invention that is claimed or of what may be claimed, but rather as descriptions of features specific to particular embodiments. Certain features that are described in this specification in the context of separate embodiments can also be implemented in combination in a single embodiment. Conversely, various features that are described in the context of a single embodiment can also be implemented in multiple embodiments separately or in any suitable sub-combination. Moreover, although features may be described above as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination can in some cases be excised from the combination, and the claimed combination may be directed to a sub-combination or a variation of a sub-combination. Similarly, while operations are depicted in the drawings in a particular order, this should not be understood as requiring that such operations be performed in the particular order shown or in sequential order, or that all illustrated operations be performed, to achieve desirable results.
[0022] Although embodiments of various methods and devices are described herein in detail with reference to certain versions, it should be appreciated that other versions, embodiments, methods of use, and combinations thereof are also possible. Therefore the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein.
Claims
1. A dressing system for use with a transcutaneous medical device, comprising: a flexible hydrophillic polyurethane matrix; an antimicrobial agent contained within the matrix, wherein the antimicrobial agent is chlorhexidine gluconate; and a haemostatic agent contained within the matrix, wherein the haemostatic agent is Kaolin in an amount to achieve a hemostatic effect wherein the dressing is formed in concentrations of 5% to 15%(w/w) Kaolin, 15%- to 25% (w/w) chlorhexidine gluconate, and a remainder hydrophillic flexible polyurethane foam.
2. The dressing system of claim 1 , wherein the dressing has an adhesive on a first surface.
3. The dressing system of claim 1 , wherein the dressing has an aperture or slit sized to receive a medical device therethrough.
4. The dressing system of claim 1 , wherein the medical device is a catheter.
5. The dressing system of claim 1 , wherein the dressing is circular.
6. The dressing system of claim 1 , further comprising a transcutaneous medical device.
7. The dressing system of claim 6, wherein the dressing includes an opening.
8. The dressing system of claim 7, wherein the opening of the dressing has a contour that conforms exactly to an outer shape of the interventional device.
9. The dressing system of claim 8, further comprising a seal member positioned on the opening.
10. The dressing system of claim 9, wherein the seal member is made of a material different than a material of the dressing.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/913,182 US20200323693A1 (en) | 2018-10-02 | 2020-06-26 | Interventional device dressing system |
US16/913,182 | 2020-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021263030A1 true WO2021263030A1 (en) | 2021-12-30 |
Family
ID=79281854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/038963 WO2021263030A1 (en) | 2020-06-26 | 2021-06-24 | Interventional device dressing system |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021263030A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897081A (en) * | 1984-05-25 | 1990-01-30 | Thermedics Inc. | Percutaneous access device |
US20130110025A1 (en) * | 2010-07-14 | 2013-05-02 | Hemcon Medical Technologies (Ip) Limited | Dressing device for use wtih a cannula or a catheter |
US20140046238A1 (en) * | 2012-08-10 | 2014-02-13 | Rebecca Leibowitz | Integrated dressing device |
US20200100944A1 (en) * | 2018-10-02 | 2020-04-02 | Pfm Medical, Inc. | Interventional device dressing system |
-
2021
- 2021-06-24 WO PCT/US2021/038963 patent/WO2021263030A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897081A (en) * | 1984-05-25 | 1990-01-30 | Thermedics Inc. | Percutaneous access device |
US20130110025A1 (en) * | 2010-07-14 | 2013-05-02 | Hemcon Medical Technologies (Ip) Limited | Dressing device for use wtih a cannula or a catheter |
US20200069475A1 (en) * | 2010-07-14 | 2020-03-05 | Bard Access Systems, Inc. | Dressing Device for use with a Cannula or a Catheter |
US20140046238A1 (en) * | 2012-08-10 | 2014-02-13 | Rebecca Leibowitz | Integrated dressing device |
US20200100944A1 (en) * | 2018-10-02 | 2020-04-02 | Pfm Medical, Inc. | Interventional device dressing system |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8674165B2 (en) | Adhesive injection site | |
EP2289574B1 (en) | Medical devices and methods of making medical devices | |
CN108451578B (en) | Dressing assembly and method of using same | |
EP1211935B1 (en) | Anti-infective covering for percutaneous and vascular access devices and coating method | |
CN103260654B (en) | A dressing device for use with a cannula or a catheter | |
JP4767503B2 (en) | Percutaneous access device and catheter kit | |
US5344415A (en) | Sterile system for dressing vascular access site | |
US8263223B2 (en) | Coated surfaces for immobilizing negatively charged anticoagulating agents from blood fluid | |
CA2375319C (en) | Clotting cascade initiating apparatus and methods of use | |
US8592639B2 (en) | Injection and hemostasis site | |
EP3860666A1 (en) | Interventional device dressing system | |
US20200323693A1 (en) | Interventional device dressing system | |
WO2021263030A1 (en) | Interventional device dressing system | |
CA3082489A1 (en) | Device and liquid compositions for securing catheters having a rigid tapered tip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21828910 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21828910 Country of ref document: EP Kind code of ref document: A1 |